Ranibizumab for refractory uveitis-related macular edema.
about
Emerging drugs for uveitisBirdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatmentImmunopathogenic Background of Pars PlanitisThe effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocolSearch strategies to identify reports on "off-label" drug use in EMBASE.The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema.Pharmacotherapy for uveitis: current management and emerging therapy.Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.Local therapies for inflammatory eye disease in translation: past, present and futureUveitis, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), and intravitreal biologics for ocular inflammation.Birdshot uveitis: current and emerging treatment optionsClinical review: Update on treatment of inflammatory macular edema.Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis.Novel Intraocular Therapy in Non-infectious Uveitis of the Posterior Segment of the Eye.Current Treatment Modalities of JIA-associated Uveitis and its Complications: Literature Review.[Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists for intravitreal treatment of macular edema in uveitis: Date: 02/07/2014].Ocular Sarcoidosis.Intravitreal therapeutic agents in noninfectious uveitic macular edema
P2860
Q24630848-AE842D30-E47F-4952-8351-AD565811546AQ26749730-0B71BD10-7A9F-4160-9782-CF4FF13219B2Q26781909-D99F5B76-17C4-41F4-B673-3775EE42D7EAQ28068067-1CE830CC-1E7E-4D1F-B839-F823BFF258CBQ30532169-5B00F474-AD2F-4691-9092-25DE410E3927Q34033983-34C9E8EE-6932-4A2F-8C29-72F3FF26D5F1Q34274075-07A6126D-599A-4826-B44E-CF2F5CB9940FQ34786343-CDD7D9C2-5D7E-41FA-9F96-A2C77766906EQ34892662-197BC6EA-F3CA-4AC0-A3EB-4EC6F56E9613Q36174993-BFDD6653-38FA-4498-B7A8-A9F1881EA9B6Q37412317-70B408B6-6389-43E3-8C5A-E04D96B30D59Q37804876-A1C08FD3-0DDC-4AB0-8094-58558FDFBFECQ38069093-E75707E6-32A0-456E-8A9F-6011166B60A5Q38211433-0018A868-7B43-4259-82E5-4704FBBF4517Q38696180-7A2E095D-F1E2-49F6-8A9E-3F90ECCABA60Q54641208-48C37400-4D9E-4697-A46A-626635F51483Q54886359-9FC8CFFE-1AEE-42B9-89C7-476608F58DECQ58806282-56C9D30E-8319-4680-99AE-4AD9655ABDD8
P2860
Ranibizumab for refractory uveitis-related macular edema.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Ranibizumab for refractory uveitis-related macular edema.
@en
Ranibizumab for refractory uveitis-related macular edema.
@nl
type
label
Ranibizumab for refractory uveitis-related macular edema.
@en
Ranibizumab for refractory uveitis-related macular edema.
@nl
prefLabel
Ranibizumab for refractory uveitis-related macular edema.
@en
Ranibizumab for refractory uveitis-related macular edema.
@nl
P2093
P1476
Ranibizumab for refractory uveitis-related macular edema.
@en
P2093
Kevin C Hong
Nisha R Acharya
Salena M Lee
P304
303-309.e2
P356
10.1016/J.AJO.2009.03.028
P407
P577
2009-05-09T00:00:00Z